Oral Calcium Salt Immediate-Release Dosage Units and the 500 mg Base Equivalent

Pharmaceutical formulators converting fosfomycin calcium into multi-dose oral tablets and capsules operate within a narrow formulation window where the calcium salt is selected over the sodium salt because of its lower gastrointestinal hygroscopicity and its suitability for solid oral delivery. The target dosage unit is typically a 500 mg base equivalent stated on the label, with the actual charge weight adjusted against the assay potency and loss on drying reported on the certificate of analysis. Release is governed by the current European Pharmacopoeia monograph for fosfomycin calcium, dissolution according to Ph. Eur. 2.9.3 or USP <711>, uniformity of dosage units according to Ph. Eur. 2.9.40 or USP <905>, elemental impurity control under ICH Q3D (R2), and stability testing under ICH Q1A (R2). Batch records for commercial lines commonly reference 21 CFR 211.165 for release testing and 21 CFR 211.111 for time limits on intermediate granule hold times.

For a 500 mg label claim in a film-coated tablet, the core weight is typically 800–850 mg, placing the API concentration between 58–62% w/w; in hard gelatin capsules with a fill weight of 650–720 mg, the API concentration rises to 69–77% w/w. Direct compression is avoided when the API particle size d90 exceeds 125 μm because content uniformity variation increases under high-speed compression. Dry granulation by roller compaction at ribbon density 1.15–1.25 g/cm³ or wet granulation in a 20 L high-shear granulator with impeller speed 300–500 rpm and chopper speed 1500 rpm is used to stabilize flow. Granules are dried in a fluid-bed dryer with inlet air 55–65 °C to a final water content not exceeding 3.0% w/w before lubricant blending with 0.5–1.0% w/w magnesium stearate. Compression is performed on rotary tablet presses with 12–20 kN compression force, and tablets are coated with an aqueous film-coating dispersion at 3–5% w/w weight gain. The main operational boundary is relative humidity: processing above 40% RH without conditioning leads to powder adhesion, and a hold time exceeding 72 h on uncoated cores has been associated with increased friability in zones without dehumidified transfer. Finished product types are 250 mg and 500 mg hard gelatin capsules, and film-coated tablets packaged in blister or HDPE bottle systems.

Granule-based oral calcium salt products intended for reconstitution into a dry suspension or for sachet dosing in pediatric and dysphagia settings require a distinct granulation sequence because the target particle size must simultaneously control content uniformity, sedimentation volume after reconstitution, and dissolution at low gastric pH. In this route, the API is dispersed at 10–15% w/w in a dry granule base containing 70–80% w/w sucrose or mannitol as the carrier, 0.2–0.5% w/w xanthan gum or sodium carboxymethylcellulose as the suspending agent, 0.05–0.10% w/w sodium benzoate for preserved multi-dose use, and 0.1–0.3% w/w colloidal silicon dioxide to prevent pre-fill caking. The in-process specification is built around granule size 150–710 μm, with a laser diffraction d50 of 180–250 μm; granules below 75 μm increase dust and content uniformity risk, while granules above 850 μm extend reconstitution time beyond 60 seconds and lower the sedimentation volume ratio. The compliance framework includes non-sterile microbial quality under Ph. Eur. 5.1.4, elemental impurities under ICH Q3D (R2), and stability under ICH Q1A (R2); wet granulation is typically conducted with purified water or an aqueous starch binder in a 20 L high-shear granulator, followed by fluid-bed drying at 50–60 °C inlet air to a final water content below 2.0% w/w.

The dried granules are screened through an oscillating sieve with a 0.71 mm mesh, then filled into PET/aluminium/polyethylene sachets or screw-cap glass bottles under ≤ 30% RH. Reconstitution is labelled to produce a 250 mg/5 mL or 500 mg/5 mL suspension, and the final product types are single-dose sachets, multi-dose dry syrups, and hospital-use unit-dose cups. One critical limitation is incompatibility with strongly alkaline taste-masking systems; when pH-modifying buffers are added to improve palatability, the calcium salt can be partially converted to the poorly absorbed free acid form if the granule microenvironment pH exceeds 7.5. Published data for this specific calcium salt reconstituted suspension configuration above 500 mg/5 mL are limited, so manufacturer-specific sedimentation and dissolution data rather than platform assumptions are used for regulatory submission.

What Limits Lyophilization Cycle Robustness for Fosfomycin Sodium 4 g Vials?

Lyophilized fosfomycin sodium vials are produced from a sterile-filtered solution containing fosfomycin sodium equivalent to 2 g or 4 g per vial, mannitol as a crystalline bulking agent at 10–20% w/w of the final lyophilized cake, and sodium hydroxide solution for pH adjustment to 7.0–7.8. The solution is prepared in Water for Injection at 8–12 °C, filtered through a 0.22 μm PVDF or polyethersulfone membrane, and filled into Type I borosilicate glass vials with chlorobutyl stoppers under isolator or restricted access barrier system grade ISO 5 conditions. The critical quality attributes include sterility according to Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins according to Ph. Eur. 2.6.14 or USP <85>, particulate matter according to Ph. Eur. 2.9.19 or USP <788>, and uniformity of filled dose under Ph. Eur. 2.9.6 or USP <905>. The manufacturing line must comply with current EU GMP Annex 1 requirements for aseptic processing, including operations under grade A with grade B background, and with ICH Q3D (R2) for elemental impurities.

The lyophilization cycle is constrained by the low-solids concentration in the fill solution and the need to avoid meltback; shelf freezing is carried out at −45 °C with a ramp of 0.5–1.0 °C/min, primary drying is run at chamber pressure 0.10–0.20 mbar and shelf temperature −20 °C, and secondary drying is run at +20 to +25 °C for 6–12 h until residual moisture is below 1.0% w/w. Frozen vials that exceed 48 h hold before primary drying in some campaigns have shown stopper-seat moisture transfer and cake shrinkage, so the fill-to-drying queue is controlled. The final product types are 2 g and 4 g powder for solution for infusion; the main limitation is that terminal sterilization is not used because the sodium salt in solution degrades at autoclave temperatures, so aseptic processing remains a non-negotiable requirement. The following release checklist is applied.

Hospital cleanroom compounding of fosfomycin sodium infusion bags is separated from industrial lyophilization by the time-dependent stability of the diluted sodium salt in 0.9% sodium chloride or 5% dextrose and by the need to manage hyperosmolarity through controlled final concentration. The product is typically compounded by reconstituting a 4 g vial with 20 mL or 50 mL Water for Injection, transferring the solution into a 250 mL PVC-free polyolefin or ethyl vinyl acetate bag, and diluting to a final concentration of 20–40 mg/mL. Peripheral intravenous administration is generally limited to 20 mg/mL and an infusion duration of 4 h because osmolality and local venous tolerance become dose-limiting above this threshold; central line administration permits 40 mg/mL. The compounding framework references USP <797> for compounded sterile preparations, current EU GMP Annex 1 for aseptic preparation, and national 503B outsourcing facility requirements where continuous production lines are used. Stability of the diluted admixture is documented as 24 h at 2–8 °C followed by immediate administration, or 12 h at room temperature, but this is matrix-dependent and requires site-specific validation under ICH Q1A (R2) stability principles.

The final product types are ready-to-use infusion bags, elastomeric pumps for outpatient parenteral antimicrobial therapy, and unit-dose syringes for neonatal or renal-adjusted dosing. The main incompatibility is with calcium-containing or bicarbonate-containing infusion fluids; admixture with these solutions can produce visible precipitation and must be avoided. Filtration during administration uses 5 μm in-line filters; 0.22 μm sterilizing filters are not used for terminal filtration of the compounded bag because the product is already sterile and additional filtration may create pump backpressure. Production batches are limited by the manual aseptic transfer steps; automated compounding devices reduce gravimetric variation in fill across 24 to 48 bags per campaign.

When Roller Compaction Replaces Direct Compression for Scored Step-Down Tablets

Scored oral calcium salt tablets intended for intravenous-to-oral step-down therapy after fosfomycin sodium infusion are manufactured by roller compaction rather than direct compression when the target core contains more than 60% w/w API and a score line is required for dose splitting. The API concentration in the core is 60–68% w/w, with microcrystalline cellulose at 20–25% w/w, mannitol at 5–8% w/w, croscarmellose sodium at 2–4% w/w, and magnesium stearate at 0.5% w/w. The primary process conflict is that high API load reduces tablet tensile strength, while the score line requires hardness above 90 N and friability below 1.0% w/w according to Ph. Eur. 2.9.7 and subdivision testing according to Ph. Eur. 2.9.8. Roller compaction is carried out with roll pressure 30–50 kN, roll gap 1.5–2.5 mm, and an integrated granulator screen 1.0 mm; the resulting ribbon density is controlled at 1.15–1.25 g/cm³ to balance recompression hardness without excessive fines.

The compressed tablets are coated with a standard aqueous film coat to 3% w/w weight gain and engraved with a one-sided or two-sided breakline. Compliance includes dissolution using Ph. Eur. 2.9.3 or USP <711> with a Q value of 75% at 30 min, uniformity of dosage units using Ph. Eur. 2.9.40 or USP <905>, and stability under ICH Q1A (R2) zones I/II. Tablet splitting performance must meet the subdivided mass uniformity criteria of Ph. Eur. 2.9.8 based on 15 split portions. Finished product types are 500 mg and 1 g scored tablets in blister packaging with Aclar/PVC or Alu-Alu to limit moisture ingress; the operational boundary is that storage above 30 °C/65% RH can shift fracture mode from brittle to ductile in the core, increasing split weight variability beyond 5% RSD in accelerated studies.

High-Dose Prolonged Infusion Vials for Carbapenem-Resistant Enterobacterales Salvage Regimens

High-load fosfomycin sodium vials of 8 g are used in hospital antibiotic stewardship programs for prolonged intravenous infusions against carbapenem-resistant Enterobacterales and extensively drug-resistant Pseudomonas aeruginosa when fosfomycin is combined with meropenem, colistin, or ceftazidime-avibactam. The susceptibility context is anchored to EUCAST 13.0 or later breakpoint tables; fosfomycin breakpoints are defined only for uncomplicated urinary tract infections in E. coli at S ≤ 32 mg/L and R > 32 mg/L, while systemic breakpoints are not universally established, so treatment is supported by identification of synergy and institutional MIC distribution data rather than a single pharmacopoeial criterion. The infusion is prepared by reconstituting an 8 g vial with 50 mL Water for Injection, transferring to a 250 mL sodium chloride 0.9% bag to yield 32 mg/mL, and administering over 3–4 h using an infusion pump with 5 μm in-line filtration. Total daily doses of 16–24 g are used in salvage regimens, requiring two to three 8 g vials per day; renal adjustment is based on institutional protocols rather than universal fixed ratios.

Manufacturing of the 8 g vial follows the same lyophilization and aseptic framework as the 2 g and 4 g presentations, but filling weight uniformity becomes more critical because fill volume per vial rises and large-headspace vials require optimized stopper treatment to prevent chamber-to-chamber moisture variation. The compliance controls include Ph. Eur. 2.6.1 or USP <71> for sterility, Ph. Eur. 2.6.14 or USP <85> for endotoxins, and ICH Q3D (R2) for elemental impurities, with release under 21 CFR 211.165. The final product type is a bulk hospital vial that is not dispensed directly to outpatients; it is converted by pharmacy into high-dose intermittent infusion bags or continuous infusion pumps. The main limitation is the absence of harmonized systemic susceptibility breakpoints for fosfomycin in carbapenem-resistant Enterobacterales, so downstream laboratories report inhibition zones and gradient strip MICs rather than relying solely on automated AST panels; published data for specific prolonged infusion stability at 32 mg/mL beyond 24 h remain limited, so each site extends stability beyond 24 h only after validated site-specific studies.